Approved indications: Steglatro (ertugliflozin) is FDA-approved as an oral add-on to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, either alone or in combination with other diabetes medicines.

Off-label uses: Clinicians may occasionally consider it off-label in adults with type 2 diabetes who also have cardiovascular or kidney disease when other SGLT2 inhibitors are not suitable, but other agents in this class with labeled heart and kidney benefits are usually preferred.

Efficacy expectations: In clinical trials, Steglatro typically reduced hemoglobin A1c by about 0.7% to 1.0% when added to background therapy, with modest weight loss (often a few pounds) and small reductions in blood pressure.

Onset and clinical outcomes: Blood sugar improvements begin within the first week, with full effect on A1c seen after about 3 months, and most patients who respond maintain stable control as long as they continue the medicine and lifestyle measures.

Comparison to similar drugs: Its glucose-lowering and weight effects are broadly similar to other SGLT2 inhibitors, but unlike some peers it does not carry specific U.S. label claims for reducing major cardiovascular events or kidney disease progression, so those outcomes are generally targeted with other members of the class when possible.

Typical adult dosing: The recommended starting dose is 5 mg taken by mouth once daily in the morning, with or without food; if additional blood sugar lowering is needed and the drug is well tolerated, the dose may be increased to a maximum of 15 mg once daily.

Kidney function considerations: Kidney function (eGFR) should be checked before starting and periodically thereafter; starting or continuing Steglatro is not recommended if eGFR is below the threshold specified in current prescribing information, and it is contraindicated in severe renal impairment or dialysis.

How to take: Swallow the tablet whole with water at about the same time each morning; it can be taken alone or with other diabetes medicines, but doses of insulin or sulfonylureas may need to be lowered to reduce hypoglycemia risk.

Special dosing instructions: Correct significant dehydration or low blood pressure before starting therapy, and your prescriber may advise stopping Steglatro at least 4 days before major surgery or any period of prolonged fasting, restarting when you are eating and drinking normally again.

Missed dose guidance: If you miss a dose, take it as soon as you remember on the same day, but skip it if it is almost time for your next dose; do not take two doses at once to make up for a missed dose.

Overdose: In case of suspected overdose, contact emergency services or a poison control center right away, as excessive dosing can lead to pronounced urination, dehydration, low blood pressure, and increased risk of ketoacidosis and kidney injury.

Common side effects: The most frequent problems are genital yeast infections (vaginal or penile), increased urination, urinary urgency, and sometimes burning or discomfort with urination; these usually appear in the first weeks to months of treatment and are often mild to moderate.

Other frequent effects: Some people experience thirst, mild dehydration, dizziness or low blood pressure, especially when also taking diuretics or if fluid intake is low.

Serious or rare adverse effects: Steglatro, like other SGLT2 inhibitors, can rarely cause diabetic ketoacidosis (DKA) even when blood sugar is not very high; urgent medical care is needed if you develop nausea, vomiting, abdominal pain, trouble breathing, confusion, or unusual fatigue.

Infections and tissue injury: Serious urinary tract infections (including kidney infections and urosepsis) and a rare but life-threatening infection of the genital/perineal area (necrotizing fasciitis of the perineum/Fournier’s gangrene) have been reported and require immediate medical attention if symptoms such as fever, severe pain, redness, swelling, or foul odor in the genital or rectal area occur.

Circulation and kidney issues: The drug can contribute to acute kidney injury in susceptible patients and has been associated with an increased risk of lower-limb complications, including amputation, particularly in people with prior amputations, severe peripheral vascular disease, or chronic foot ulcers.

Warnings and precautions: It is not recommended for use to control blood sugar in type 1 diabetes and should not be used in patients with severe renal impairment, end-stage kidney disease, or those on dialysis.

Special populations: Use is not approved in children or adolescents; in older adults and in those with low blood pressure, dehydration, diuretic use, or kidney disease, there is a higher risk of volume depletion and kidney problems, so closer monitoring is needed.

Pregnancy and breastfeeding: Because SGLT2 inhibitors may affect kidney development, use during the second and third trimesters of pregnancy is generally avoided, and breastfeeding while taking Steglatro is not recommended.

Relative safety versus other options: Overall, its side-effect profile is similar to other SGLT2 inhibitors, with benefits in weight and blood pressure balanced against risks of genital infections, DKA, and volume depletion; compared with many older diabetes drugs, it has a low risk of hypoglycemia when not combined with insulin or sulfonylureas.

Reporting side effects: Side effects should be reported to a healthcare professional and can also be reported directly to the FDA’s MedWatch program (online or by phone) to help track ongoing safety information.

Interactions with other diabetes medicines: When Steglatro is combined with insulin or insulin secretagogues such as sulfonylureas, the risk of low blood sugar increases, so doses of those other medicines may need to be reduced.

Drugs affecting blood pressure or fluid balance: Diuretics (water pills), ACE inhibitors, ARBs, and other blood pressure–lowering drugs can have additive effects with Steglatro on lowering blood pressure and reducing blood volume, raising the risk of dizziness, fainting, or kidney problems.

Kidney-impacting medicines: Frequent or high-dose use of NSAIDs (such as ibuprofen or naproxen) or other nephrotoxic drugs may increase the chance of kidney injury when combined with Steglatro, especially in people who are dehydrated or have existing kidney disease.

Alcohol and dietary factors: Heavy alcohol use, very low-carbohydrate or ketogenic diets, and prolonged fasting can increase the risk of ketoacidosis when taking Steglatro and should be discussed with a clinician.

Imaging and procedures: Because both Steglatro and iodinated contrast dye used in some imaging tests can stress the kidneys, clinicians may temporarily hold Steglatro around the time of contrast studies or major procedures in higher-risk patients.

Conditions requiring extra caution: Use requires caution or may be inappropriate in people with severe renal impairment, recurrent genital or urinary infections, history of diabetic ketoacidosis, peripheral arterial disease or prior lower-limb amputation, chronic foot ulcers, very low blood pressure, or frequent dehydration.

Monitoring needs: Regular monitoring typically includes blood glucose and A1c, kidney function (eGFR and serum creatinine), blood pressure, and periodic checks for signs of genital or urinary infections; ketone testing may be recommended during illness, fasting, or if symptoms suggest ketoacidosis.

Q: What is Steglatro used for?
A: Steglatro is an oral SGLT2 inhibitor used along with diet and exercise to help lower blood sugar in adults with type 2 diabetes, either alone or with other diabetes medicines.

Q: How long does it take for Steglatro to start working?
A: The medicine begins lowering blood sugar within the first few days, but its full effect on A1c is usually seen after about 2 to 3 months of consistent daily use.

Q: Will Steglatro cause weight loss?
A: Many people lose a small amount of weight because extra sugar and fluid are passed in the urine, but the amount of weight loss varies and is usually modest.

Q: Can I take Steglatro with metformin or insulin?
A: Yes, Steglatro is often combined with metformin and can be used with insulin or other diabetes drugs, though doses of insulin or sulfonylureas may need adjustment to reduce the risk of low blood sugar.

Q: Is Steglatro safe for my kidneys?
A: Steglatro should not be used in people with significantly reduced kidney function or on dialysis, and kidney function should be monitored over time; in people with adequate kidney function, it is generally safe when used as directed but can still rarely contribute to kidney injury, especially if you become dehydrated.

Q: What should I do if I get sick while taking Steglatro?
A: If you have vomiting, diarrhea, high fever, or cannot eat or drink normally, contact your healthcare provider promptly, as you may need to temporarily stop Steglatro and be checked for dehydration or ketoacidosis.

Q: Do I need to stop Steglatro before surgery?
A: Many clinicians recommend stopping Steglatro at least 4 days before major surgery or procedures requiring prolonged fasting to lower the risk of ketoacidosis, restarting it when you are stable and eating again.

Storage: Store Steglatro tablets at room temperature (generally 68°F to 77°F or 20°C to 25°C), in the original container, tightly closed, away from excess heat and moisture, and out of the reach of children and pets.

Disposal: Do not flush unused tablets down the toilet or pour them into drains; instead, use a drug take-back program if available or follow local pharmacy or community guidance for safe disposal, and if none is available, mix tablets (without crushing) with an undesirable substance in a sealed container before throwing them in the household trash.